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Nocturnal hypoxemia, night-day arterial pressure changes and left
ventricular geometry in dialysis patients. It is well established that
nocturnal hypoxemia in sleep apnea causes an inversion of the circadian
arterial pressure rhythm and triggers nocturnal hypertension. Since sleep
apnea is very frequent in dialysis patients, we hypothesized that nocturnal
hypoxemia may be a factor that contributes to alter the 24-hour arterial
pressure profile in these patients. To test the hypothesis 32 dialysis
patients underwent 24-hour blood pressure (BP) monitoring and contin-
uous monitoring of arterial O2 saturation during the night-time. Hemo-
dialysis patients were studied during the non-dialysis day. All patients
underwent an echocardiographic study. Thirteen patients had no episode
of nocturnal hypoxemia (group I), 7 had at least one episode overnight but
less than 2 episodes/hr (group II) and 12 had $ 2 episodes/hr (group III).
The average daytime systolic pressure was similar in the three groups.
However, the average nocturnal systolic pressure fell in the first group
(22.5 6 4.2%) and rose in the second (12.0 6 3.6%) and in the third
(13.9 6 2.2%) group (one way ANOVA, P , 0.005). The relative wall
thickness of the left ventricle (RWT) was significantly (P , 0.05) higher in
group III than in group I, and in the aggregate (N 5 32) there was an
inverse relationship between average nocturnal SaO2 and RWT (r 5
20.43, P 5 0.015). The proportion of patients with concentric remodeling
or concentric hypertrophy was higher (P 5 0.05) in the group with a more
severe degree of nocturnal hypoxemia (group III, 8 of 12) than in the other
two groups (group I, 3 of 13; group II, 2 of 7). Nocturnal hypoxemia is
associated with the “non-dipping” arterial pressure profile in dialysis
patients. Disturbed respiratory control during the night may represent an
important cardiovascular risk factor in dialysis patients.
The inability to maintain the circadian profile is an important
feature of the altered arterial pressure control in patients with
chronic renal failure. Indeed, these patients very frequently fail to
show the physiological decrease during night-time (“non-dipping”
profile) [1–12]. Various hypotheses have been proposed to explain
such alteration [2, 4, 5] (see Discussion). We thought that
episodes of oxygen desaturation, triggered by sleep apnea, which
is very frequent in the dialysis population [13–24; reviewed in 19],
could be a contributory factor. Sleep apnea in the general
population represents a well established cause of nocturnal hy-
pertension [25, 26], and it is frequently associated with primary
hypertension [reviewed in 27, 28], as well as with severe cardio-
vascular complications [29–31]. Therefore, in this study we sought
whether nocturnal hypoxemia is related with altered night-day
arterial pressure changes as well as with deranged left ventricular
geometry in uremic patients.
METHODS
Patients
Thirty-two patients (19 male and 13 female) out of 120 patients
on chronic dialysis who were being treated at our institution and
at an affiliated dialysis center accepted our request to take part in
the study. The exclusion criteria were (a) pre-existing pulmonary
disease in 27 patients (defined on the basis of medical history,
physical examination, chest radiography and respiratory func-
tional tests when indicated), (b) diabetes mellitus in 23, (c)
symptomatic heart failure in nine, (d) severe hypertension con-
traindicating the withdrawal of antihypertensive treatment in one,
(e) occluded brachial artery in five, and (f) AL amyloidosis in two.
The remaining 21 patients either refused or could not participate
for logistical reasons. Thus, the 32 patients who participated in the
study represented the 60% of all eligible cases. Their mean age
was 48 years (range 17 to 79 years) and the duration of dialysis
treatment was six years (range 1 to 21 years). The cause of chronic
renal disease was chronic glomerulonephritis in nine cases, poly-
cystic kidney in five, interstitial nephritis in three, Alport syn-
drome in two, nephroangiosclerosis in one, cortical necrosis in
one, pyelonephritis in one, Laurence-Moon-Bardet Biedle syn-
drome in one, gouty nephropathy in one, and undefined in eight
cases. No patient had had myocardial infarction or cerebrovascu-
lar events. None was a habitual smoker or a heavy drinker or a
frequent user of sedative drugs. Twenty-one patients were on
hemodialysis and were being treated thrice weekly with standard
bicarbonate dialysis (Na 138 mmol/liter, HCO3 35 mmol/liter, K
1.5 mmol/liter, Ca 1.25 to 1.75 mmol/liter, Mg 0.75 mmol/liter)
and 1.1 to 1.7 m2 hollow-fiber or flat plat Cuprophan dialyzers.
The average urea Kt/V in these patients was 1.32 6 0.40. The
remaining 11 patients were on CAPD (weekly Kt/V 1.82 6 0.20).
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Eleven patients were on treatment with erythropoietin (6 hemo-
dialysis patients and 5 CAPD patients). Eleven were taking
antihypertensive drugs [Ca-channel blockers in 10 cases (which
were associated with beta-blockers in 3, with clonidine in 1 and
with captopril plus clonidine in 1) and clonidine in the remaining
case]. Because antihypertensive drugs can interfere with the
night-day arterial pressure changes in patients with chronic renal
failure [32, 33], these medications were stopped at least one week
before the study.
Protocol and methods
The protocol was conformed with the ethical guidelines of our
institution and informed consent was obtained from each partic-
ipant. The study was performed during the day off dialysis. The
patients were admitted in the nephrology ward of our Unit
between 7 a.m. and 7:30 a.m., in standard hospital rooms.
Twenty-nine studies were performed with patients sleeping in a
quiet single bed room. The remaining three patients slept in a
double room. The bedmates of these three patients were in stable
condition and did not need night care.
Arterial pressure monitoring
Twenty-four hour arterial pressure monitoring (Takeda 2420,
model 7) was started between 7:00 and 7:30 a.m. Measurements
were done every 15 minutes both during the day (7 a.m. to
11 p.m.) and during the night (11 p.m. to 7 a.m.). The calibration
of the ambulatory recorder was performed against a mercury
sphygmomanometer before each recording. Patients were in-
structed to maintain the level of activity of a normal day spent
indoors at home.
Nocturnal pulse oximetry
Pulse oximetry was measured by means of the Ohmeda-Biox
3700 digital pulse oximeter (Pabish, Milan, Italy), placing the
sensor on the patient’s index finger. The recordings were done
between 11 p.m. and 7 a.m. and for a further hour after awaking.
A fall in oxygen saturation was considered to be significant if the
oxygen desaturation during that episode was . 4% than minimum
oxygen saturation during the control period in awake conditions
[34]. The minimal oxygen saturation (SaO2) and average noctur-
nal SaO2 levels were obtained by using the standard software
provided with the Ohmeda Biox pulse oximeter.
Echocardiography
The day after dialysis each patient underwent an echocardio-
graphic study and all echocardiographic measurements were
performed according to the recommendations of the American
Society of Echocardiography [35] by an observer unaware of
arterial pressure and SaO2 recordings. Left ventricular mass
(LVMI) was calculated according to the Devereux formula [36]
indexed for body surface area. Relative wall thickness was calcu-
lated by the standard formula RWT 5 2 PWT/LVEDD (cut-off
value $ 0.45). Geometric analysis of the left ventricle was
performed according to Koren et al [37]. Presence or absence of
left ventricular hypertrophy (LVH) was defined on the basis of a
LVMI greater than or less than 125 g/m2. A normal RWT and no
LVH was defined as normal geometry; LVH was classified as
concentric when RWT was $ 0.45 and eccentric when RWT
was # 0.45. The pattern of increased RWT without LVH is
defined concentric remodeling.
Definitions and data analysis
Patients were arbitrarily classified as “non-dippers” when their
night-day systolic pressure ratio was $ 100% because this thresh-
old approximates the 95th percentile of the night-day ratio in 4765
normotensive subjects reported in a recent meta-analysis [38]. A
ratio $ 100% mathematically corresponds with a night-time
systolic pressure equal to or higher than daytime pressure. This
ratio depends less on BP level than on the nocturnal BP fall and
is to be preferred in the definition of dipping status [38].
Data are presented as mean6 SD and median (interquartile
range) and analyzed by parametric and non-parametric tests, as
appropriate. Between groups comparisons were made by one-way
ANOVA followed by the Newman-Keuls test for multiple com-
parisons or by Kruskall Wallis statistic. Proportions were com-
pared by the chi-square test. Relationships between paired pa-
rameters were analyzed by the least square method (continuous
variables) or by the Spearman rank test (discontinuous variables).
Multifactorial hypotheses were tested by multiple regression
analysis.
RESULTS
Overnight oxygen saturation profile
During the control period in awake conditions, the average
oxygen saturation (SaO2) in the whole group of dialysis patients
was 97.3 6 1.4%. During night-time nineteen patients had at least
one desaturation episode, while the remaining thirteen had no
episode. The median of the number of oxygen desaturation
episodes overnight was 16 (interquartile range 6 to 37 episodes),
while the mean values of the average nocturnal SaO2 and of the
average minimum SaO2 were 95.4 6 3.0% and 80.8 6 15.0%,
respectively. In the patients with at least one episode of nocturnal
hypoxemia the number of oxygen desaturation episodes was
inversely and very strictly related to the severity of oxygen
desaturation (r 5 20.94, P , 0.001) without any difference
between hemodialysis and CAPD patients (Fig. 1). On the basis of
the results of the nocturnal pulse oximetry study, patients were
divided into three groups: thirteen patients with no episode of
Fig. 1. Relationship between the number of episodes of nocturnal hypox-
emia and the minimal SaO2. Symbols are: (E) CAPD patients; (F) HD
patients. r 5 2 0.94; P , 0.001.
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desaturation (group I), seven with at least one episode of desatu-
ration during the whole recording period but less than two
episodes/hr (group II), and twelve with a consistent desaturation
pattern ($ 2 desaturation episodes/hr; group III).
Twenty-four hour arterial pressure monitoring
As shown in Table 1, the average 24-hour arterial pressure in
patients with nocturnal hypoxemia (group III) tended to be higher
than in those without (group I), but the difference was not
significant. The daytime systolic pressure was almost identical in
the three groups (group I, 143 6 22 mm Hg; group II, 141 6 23
mm Hg; group III, 143 6 31 mm Hg). However, the average
nocturnal systolic pressure changes showed a different pattern in
the three groups (one way ANOVA, P , 0.005) because there was
a 22.5 6 4.2% decrease in the group without nocturnal hypox-
emia (group I), an inverted pattern in the group with nocturnal
hypoxemia (group III) with a 13.9 6 2.2% increase (P , 0.01 vs.
group I), and an intermediate behavior in group II with average
increase 12.0 6 3.6% (P , 0.05 vs. group I; Fig. 2). In the
aggregate the night-day systolic pressure % change was inversely
related with the number of episodes of nocturnal hypoxemia
(rS 20.40, P 5 0.02). The average daytime diastolic pressure
tended (P 5 0.07) to be higher in group III (88 6 20 mm Hg) than
in the other two groups (group I, 78 6 16 mm Hg; group II, 80 6
8 mm Hg), but nocturnal diastolic pressure changes did not differ
significantly (group I, 10.6 6 6.4%; group II 25.0 6 3.5%; group
III, 20.3 6 5.2%).
The average 24-hour heart rate was similar in the three groups
(Table 1), and the daytime heart rate as well as night-time changes
were again very similar (group I, 78 6 7 beats/min, 26.5 6 11.1%;
group II, 80 6 7 beats/min, 25.2 6 3.9%; group III, 83 6 7
beats/min, 26.6 6 6.0%).
Fig. 2. Average nocturnal % changes in systolic pressure in the three
groups. Nocturnal % Changes were calculated (hour by hour) by the
formula:
Night-time systolic pressure ~hourly averages! 2
Average daytime systolic pressure
Average daytime systolic pressure 3 100
Negative values indicate a fall in systolic pressure at night.
Table 1. Clinical and biochemical data, ambulatory monitoring and pulse oximetry in the three groups
Group I
(no episode of O2 des.)
N 5 13
Group II
(at least 1 episode of O2
des. overnight but ,2/hr)
N 5 7
Group III
($2/hr episodes of O2 des.)
(N 5 12)
Age years 45.2 6 19.7 54.6 6 19.3 46.4 6 12.6
Males/females 9/4 2/5 8/4
BMI kg/m2 23.4 6 3.5 25.8 6 3.5 26.4 6 3.9
Duration of dialysis treatment
years (median, interquartile
range)
2.0 (1.0–13.0) 2.0 (1.0–7.0) 3.0 (2.25–6.5)
Serum Na mMol/liter 139 6 4 138 6 6 138 6 4
Serum K mmol/liter 4.8 6 0.8 4.70 6 1.0 5.3 6 0.7
Serum albumin g/dl 4.0 6 0.6 4.2 6 0.1 4.3 6 0.5
Hematocrit % 32 6 7 31 6 3 33 6 7
PTH pg/ml (median, interquartile
range)
74 (10–306) 95 (5–342) 322 (101–594)
Pulse
Min SaO2 in awake conditions
%
92.7 6 3.6 94.7 6 2.3 91.7 6 3.9
Min SaO2 during night-time % 91.1 6 3.2 88.1 6 4.3 76.6 6 17.4
Average nocturnal SaO2 97.2 6 1.2 96.2 6 2.1 94.9 6 3.3
Number of O2 des. episodes/hr
(median, interquartile range)
0 (0–0) 0.6 (0.2–0.7) 3.2 (2.0–7.7)
Ambulatory monitoring
Arterial pressure
24 hr average systolic
pressure
138 6 22 141 6 27 143 6 30
24 hr average diastolic
pressure
75 6 13 77 6 11 86 6 19
Heart rate
24 hr average HR 75 6 11 78 6 6.3 81 6 9.8
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When patients were categorized on the basis of the individual
night-day arterial pressure ratio into non-dippers (ratio $ 100%)
and dippers (ratio ,100%), 15 patients fell into the first category.
The median number of SaO2 desaturation episodes was much
higher (P 5 0.005) in non-dippers (14 episodes, interquartile
range 4 to 37) than in dippers (0, interquartile range: 0 to 7).
Echocardiographic data
The PWT (P 5 0.06) tended to be higher in patients with
nocturnal hypoxemia (group I), while the IVST, the LVEDD and
the LVMI were similar in the three groups (Table 2). The RWT
was significantly increased in patients with nocturnal hypoxemia in
comparison with those without hypoxemia (one-way ANOVA P 5
0.044, group III vs. group I, P , 0.05) and in the aggregate there
was an inverse relationship between average nocturnal SaO2 and
RWT (r 5 20.43, P 5 0.0015). Furthermore, separate analysis of
dippers and non-dippers revealed a highly significant inverse
correlation (r 5 20.66, P 5 0.008) between minimal nocturnal
SaO2 and RWT in non-dippers (Fig. 3), while no such correlation
was found in the dippers (r 5 0.06, NS).
Correlates of left ventricular geometry
The hematocrit, nocturnal hypoxemia (either expressed as
average nocturnal SaO2 or as number of nocturnal episodes of O2
desaturation) and serum parathyroid hormone (PTH) were the
only parameters to be significantly related with the echocardio-
graphic measures of the left ventricle (Table 3). The hematocrit
predicted both the PWT and the LVMI while nocturnal hypox-
emia predicted the PWT as well as the RWT (Table 3). Parathy-
roid hormone was directly related with the RWT. In a multiple
regression model average nocturnal SaO2 and serum PTH pre-
dicted the 27% of RWT (r 5 0.52, P 5 0.013; SaO2, b 5 20.38;
PTH, b 5 0.31), while age, duration of dialysis treatment, body
mass index (BMI), arterial pressure and hematocrit did not add
any significant prediction power to the model. The proportion of
patients with concentric remodeling or concentric hypertrophy
was higher (x2 5 3.809, P 5 0.05) in the group with nocturnal
hypoxemia (8 of 12) than in the other two groups (group I, 3 of 13;
group II, 2 of 7; Fig. 4).
DISCUSSION
In this study nocturnal hypoxemia in dialysis patients was
associated with the non-dipping profile and, independently of
arterial pressure, with concentric hypertrophy and remodeling.
Chronic renal failure is commonly associated with a blunted or
inverted circadian arterial pressure curve [1–13]. Mainly on
theoretical considerations, this phenomenon has been attributed
to extracellular volume expansion [2], overactivity of the sympa-
thetic system [4], uremic neuropathy [6], and frequent arousals
associated with periodic leg movements and restless legs syn-
drome [39]. Episodes of nocturnal hypoxemia triggered by sleep
apnea represent a potential cause of nocturnal hypertension that
has not been previously considered. Seminal studies by Millman et
al [14], Fein et al [15] and Kimmel, Miller and Mendelson [16] in
the eighties as well as more recent studies [17–24] clearly estab-
lished that sleep apnea syndrome, mainly of the obstructive type,
is very frequent in the dialysis population with a prevalence
ranging from 21% to 47% [21], and equally common in hemodi-
alysis and CAPD patients [19]. Sleep apnea in the general
population is consistently associated with an altered circadian
arterial pressure rhythm [25, 26], and the severity of nocturnal
hypoxemia is strictly related with the night-day systolic pressure
change [25]. Hypoxemia is considered the primary factor respon-
sible for the cardiovascular effects of sleep apnea [26, 27] because
it induces a chemoreceptor mediated increase in efferent sympa-
thetic activity, triggers the release of epinephrine in the adrenal
medulla and alters the endothelial production of nitric oxide.
Furthermore, sleep apnea is now considered an important cardio-
vascular risk factor [29–31], and in a follow-up study it was
associated with a high incidence of myocardial infarction and
stroke, while these cardiovascular complications were almost fully
prevented by tracheostomy [30].
Fig. 3. Relationship between minimal nocturnal oxygen saturation
(SaO2) and relative wall thickness (RWT) in non-dippers dialysis pa-
tients. Abscissa, ranked SaO2 data: rank 1 is the most severe case (minimal
SaO2 5 53%) and rank 15 the less severe case (minimal SaO2 5 93%).
r 5 20.66; P 5 0.008.




Group I 0.98 6 0.20 1.10 6 0.28 5.1 6 0.64 127.8 6 41.8 0.19 6 0.04
Group II 1.00 6 0.24 1.11 6 0.25 4.6 6 0.61 106.0 6 35.4 0.22 6 0.05
Group III 1.17 6 0.28 1.19 6 0.19 4.8 6 0.53 131.6 6 54.3 0.24 6 0.05a
Abbreviations are: PWT, posterior wall thickness; IVST, interventricular septum thickness; LVEDD, left ventricular end diastolic diameter; LVMI,
left ventricular mass index; RWT, relative wall thickness.
a P , 0.05 vs. group I. The difference in PWT between group I and III just failed to reach statistical significance (P 5 0.06).
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In the present study we found that the night-day systolic
pressure change is reversed in dialysis patients with nocturnal
hypoxemia and that this alteration is inversely related with the
number of episodes of hypoxemia. Accordingly, the number of
episodes of nocturnal hypoxemia was much higher in non-dippers
than in dippers. This study is the first to associate the non-dipping
phenomenon to nocturnal hypoxemia in dialysis patients. Having
not performed polysomnographic recordings, nocturnal hypox-
emia in our patients may not necessarily reflect sleep apnea.
However, none of our patients had concomitant diseases or
factors interfering with respiratory control. Nocturnal pulse oxim-
etry is very useful in ruling out sleep apnea (negative predictive
value of 97%). Its diagnostic sensitivity (98%) is also very high but
the positive predictive value of this method is rather limited
(61%) [34]. Pulse oximetry reliably detects hypoxemia in dialysis
patients [39]. Thus, we believe that the most likely cause of
hypoxemia in our patients was a disturbed respiratory control
during sleep. Whatever the relationship between hypoxemia and
sleep apnea in dialysis patients, it is important to note that studies
in rats submitted to recurrent episodic hypoxia [40] or to contin-
uous hypobaric hypoxia [41], as well as experimental observations
in healthy humans [42] have consistently demonstrated that
hypoxemia per se activates a series of reflex cardiovascular re-
sponses, which, mainly via sympathetically mediated vasoconstric-
tion, provoke an important arterial pressure increase. It is worth
noting that although the link between hypoxemia and the night-
day arterial pressure changes in this study was a consistent one, it
remains to be seen whether it entails a causal relationship or
represents a mere association. Continuous positive airway pres-
sure lowers arterial pressure in hypertensive patients with sleep
apnea [43, 44], and the stepwise reduction of this treatment is
associated with a proportional arterial pressure increase [45],
suggesting a causal link. It should be noted that the average
nocturnal fall in systolic pressure in non-hypoxemic patients was
rather small (22.5%) and less than that observed in age-matched
healthy subjects [38], which indicates that factors other than
hypoxemia play an important role in the altered circadian arterial
pressure profile in dialysis patients.
Independently of hypertension, patients with sleep apnea dis-
play an increase in left ventricular mass as well as in posterior wall,
and interventricular septum thickness in the presence of unaltered
left ventricular end diastolic diameter [46] (that is, a geometric
pattern indicating concentric hypertrophy). Similarly, we noted
that nocturnal hypoxemia in dialysis patients was associated with
concentric hypertrophy or remodeling. Concentric hypertrophy as
well as concentric remodeling [47] entail an elevated risk for
cardiovascular disease and death that is independent of arterial
pressure. In dialysis patients concentric hypertrophy has an ad-
verse clinical outcome [48] and the expected median survival in
these patients is only 48 months. Thus, our finding that nocturnal
hypoxemia is associated with concentric hypertrophy or remodel-
ing, independently of other well established predictors of left
Fig. 4. Patients with concentric remodeling (f) and concentric hypertro-
phy (M) in the three groups.
Table 3. Correlation matrix of the relationships between echocardiographic parameters and clinical, biochemical, ambulatory monitoring and pulse
oximetry results
PWT LVEDD LVMI RWT
r (P)
Age 0.23 (0.20) 0.13 (0.48) 0.10 (0.58) 0.33 (0.06)
Duration of RDT 0.08 (0.66) 0.09 (0.63) 0.19 (0.29) 0.07 (0.72)
BMI 0.07 (0.68) 0.014 (0.94) 0.08 (0.66) 0.25 (0.17)
Hematocrit 20.42 (0.01) 20.18 (0.32) 20.37 (0.04) 20.27 (0.13)
Albumin 0.04 (0.83) 0.08 (0.67) 0.0 (0.83) 0.05 (0.79)
PTH 0.32 (0.08) 20.13 (0.49) 0.21 (0.25) 0.36 (0.05)
24 hr systolic BP 0.05 (0.78) 0.28 (0.12) 0.15 (0.42) 0.10 (0.57)
24 hr diastolic BP 0.07 (0.68) 0.06 (0.72) 0.01 (0.94) 0.02 (0.89)
Daytime systolic BP 0.04 (0.84) 0.29 (0.10) 0.15 (0.41) 20.14 (0.46)
Daytime diastolic BP 0.04 (0.82) 0.05 (0.77) 0.03 (0.88) 20.01 (0.93)
night-time syst 0.08 (0.65) 0.23 (0.20) 0.15 (0.41) 20.04 (0.82)
night-time diast 0.12 (0.49) 0.08 (0.65) 0.02 (0.92) 0.07 (0.66)
night-day systolic ratio 0.13 (0.46) 0.05 (0.78) 0.07 (0.71) 0.20 (0.28)
night-day diastolic ratio 0.21 (0.24) 0.10 (0.56) 0.11 (0.55) 0.21 (0.25)
Min. nocturnal SaO2 20.27 (0.13) 0.12 (0.52) 0.02 (0.89) 20.34 (0.06)
Average nocturnal SaO2 20.34 (0.06) 20.16 (0.38) 20.05 (0.78) 20.43 (0.01)
Number of episodes of O2 des. 0.34 (0.05) 0.15 (0.40) 0.01 (0.94) 0.41 (0.02)
Abbreviations are in Table 2.
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ventricular hypertrophy such as older age, hypertension and
anemia while on dialysis [48], suggests that it may represent an
important cardiovascular risk factor in dialysis patients. A limita-
tion of our study is the relatively small sample size. Further studies
of larger dimensions are warranted to investigate the role of
nocturnal hypoxemia in the high cardiovascular risk of dialysis
patients.
Reprint requests to Prof. Carmine Zoccali, CNR Centro Fisiologia Clinica,
Via Sbarre Inferiori 39, Reggio Cal 89100, Italy.
E-mail: czoccali@diel.it
APPENDIX
Abbreviations in this article are: BP, blood pressure; IVST, interven-
tricular septum thickness; LVEDD, left ventricular end diastolic diameter;
LVH, left ventricular hypertrophy; LVMI, left ventricular mass index;
PWT, posterior wall thickness; RWT, relative wall thickness; SaO2, oxygen
saturation.
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